Pharma Companies Strategies – Key Facts & Challenges – Edition 2011

 

Embed or link this publication

Description

This third book published by Smart Pharma Consulting offers 110 illustrated slides to help you assess the strategies and performances of the 35 leading pharmaceutical companies in the world.

Popular Pages


p. 1

new book from smart pharma consulting available since november 10 2011 jean-michel peny pharma companies strategies key facts challenges 2011 edition smart pharma consulting pharma companies strategies key facts challenges 2011 edition provides a fact-based analysis of the evolution of the pharmaceutical market and evaluate the strategy and the performance of 35 leading pharmaceutical companies the author shares his strategic vision of the market evolution and answers to the question does pharma companies size count by comparing the strategic priorities and the corresponding performance of big mid pharma companies the key facts and figures of the 35 analyzed pharmaceutical companies have been summarized in a one-page identity card allowing a user-friendly review and comparisons publisher smart pharma consulting ­ 123 pages ­ 150 w taxes jean-michel peny is president of the strategy and management consulting firm smart pharma consulting director of smart pharma institute of management lecturer in pharmaceutical strategy and marketing at escp-europe and essec business schools and at the faculty of pharmaceutical sciences paris xi

[close]

p. 2

order pharma companies strate key facts challenges 2 i wish to purchase hard copies of the book pharma compani address mentioned below for delivery in france the price is of 150 per copy of the book p account located in france or order a bank transfer net of charge 0020 092 for delivery in all other countries the price is of 170 per copy of pharma consulting iban fr76 3007 6021 1716 5131 0020 092 for 20 or more hard copies purchased version pdf of the boo fill in return order form to one of the following email jmpeny@smart-pharma.com fax +33 1 45 57 46 59 postal address smart pharma consulting 1 rue houdart de lamotte 75015 pa the book will be mailed with an invoice through express delivery shipping address first name job title last name company name address postcode city country e-mail address phone smart pharma consulting 1 rue houdart de lamotte 75015 paris ­ france tel +3 n° siret 438 462 145 000 22 n° in

[close]

p. 3

smart pharma consulting nies strategies insights 2011 by jean-michel peny ies strategies key facts challenges 2011 and receive it at the please enclose a check payable to smart pharma consulting from a bank es in favor of smart pharma consulting iban fr76 3007 6021 1716 5131 the book net of charges please order a bank transfer in favor of smart 2 swift bic nordfrpp you will receive for free an electronic ok at your e-mail address aris ­ france invoicing address first name job title last name company name address postcode city country e-mail address 1 publisher phone smart pharma consulting ­ 123 pages ­ written in english 33 0 6 11 96 33 78 fax +33 0 1 45 57 46 59 email jmpeny@smart-pharma.com ntracommunautaire fr 024 384 621 45

[close]

p. 4

110 illustrated slides to help you assess the strategies and performances of the leading pharma companies strategic segments 2010 big pharma companies of total revenues 100 others 80 generics vaccines 1 otc consumer health mid pharma companies of total revenues other businesses not healthcare usd 575 bn 81 13 22 4 22 4 49 9 usd 81 bn 3 3 12 15 usd 119 bn 8 7 7 6 5 4 usd 7 bn <2 24 other businesses not healthcare 100 animal health royalties licensing fees contract manufacturing etc others generics vaccines 1 otc consumer health 1 1 80 16 20 60 60 99 82 branded ethical company 2010 drugs2 5 66 royalties licensing fees contract manufacturing etc 40 branded ethical drugs2 401 70 revenues by 50 62 medical devices 40 leading =87 diagnostics big pharma companies 20 20 =94 mid pharma companies otsuka 11.1 12.4 medical j&j daiichi sankyo 61.6 61.6 10.3 devices 11.0 <1 10 diagnostics 10.8 10.9 novartis 50.6 51.6 0 0 novo nordisk astellas segments 9.8 10.9 roche segments all other segments all other segments 45.5 47.1 eisai 8.3 8.8 merck co 44.1 46.0 merck k hc 7.8 8.3 gsk 43.9 44.6 1 average 2010 federal reserve exchange rate gilead 7.4 7.9 source companies annual reports 2010 smart pharma consulting analyses sanofi 40.3 42.5 mylan 5.5 5.5 abbott 32.4 35.2 allergan 4.8 4.9 astrazeneca 33.1 34.2 biogen 3.6 4.7 lilly 22.4 23.1 csl 4.6 4.7 bayer hc 22.5 22.8 4.4 4.7 key financial data name novartis country switzerland mitsubishi bms 19.5 19.5 forest 4.2 4.4 boehringer i 15.8 key segments 18.7 key products chugai 12/10 12/09 growth usd 4.3 million 4.3 alcon takeda 16.2 51,561 45,103 14.3 ucb share of 3.7 revenues 4.3 canada 16.2 international sales yoy latin america teva 50,624 44,267 14.4 15.5 16.1 3 net sales nycomed 4.2 usd million change net sales 4.0 9 revenues revenues 15.5 amgen 14.7 15.1 11,526 9,982 genzyme operating profit 4.0 6,053 1.diovanbn1 0.7 12 4.0 2010 in usd franchise in usd bn1 europe baxter asia africa 12.8 net sales 11.1 celgene antihypertensive agent 22.4 22.1 3.5 operating profit margin 3.6 autralasia 37 50,624 9,07010 7,469 21.4 r&d expenses 4,265 8.1 08 0 18 20 40 60 2.gleevec80 5 15 usd million pfizer 66.7 67,8 antineoplastic agent healthcare products international non u.s source companies annual reports united states pharma consulting analysesophthalmologic agent 2010 smart data for alcon inc royalties 1,533 3.lucentis licensing and manufacturing fees 3 24.4 4.zometa of revenues other 1 17.6 16.6 average 2010 federal reserve exchange rate 33 are not available 1,511 1,376 rx branded drugs generics vaccines otc consumer health medical devices diagnostics other healthcare animal health other segments 61 17 6 10 2 2 2 calcium regulator antineoplastic agent 2.9 8.7 3 4 pipeline number of compounds at each stage 5.femara phase i oncology cardiovascular metabolism neuroscience ophthalmics respiratory other integrated hospital care 1 phase ii 3 2 3 3 3 phase iii 2 3 1 3 3 filing 3 2 2 1 6.sandostatin endocrine-metabolic agent 1,291 1,003 11.8 5.1 2 0 7.exelon franchise cns agent alzheimer s strategic priorities extend lead in innovation research driven by a distinctive scientific and clinical strategy focusing on unmet medical need and knowledge of disease accelerate growth tailor commercial model to the rapidly changing healthcare environment leveraging the broad portfolio to expand aggressively in emerging and established markets deal strategy by acquiring in 2010 the nestlé s remaining 52 interest in alcon novartis increased its interest to a controlling interest of 77 and got the opportunity to merge alcon into novartis in 2010 with the acquisition of corthera novartis gained worldwide rights to relaxin sandoz completed the 100 acquisition of the privately held us based oriel therapeutics inc to broaden its portfolio of projects in the field of respiratory drugs source company annual report and 20-f form exercise ended 12-2010 smart pharma consulting analyses to order pharma companies strategies 2011 please fax or e-mail the order form inside this leaflet or contact directly smart pharma consulting smart pharma consulting 1 rue houdart de lamotte ­ 75015 paris ­ france tel +33 6 11 96 33 78 fax +33 1 45 57 46 59 e-mail jmpeny@smart-pharma.com

[close]

Comments

no comments yet